Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ELETRIPTAN

All products: not a benefit

Other products in the same Health Canada class (N02CC) — coverage varies; not interchangeable

  • Almotriptan (Axert): not a benefit
  • Frovatriptan (Frova): not a benefit
  • Naratriptan (Amerge): not a benefit
  • Rizatriptan (Maxalt RPD): not a benefit
  • Sumatriptan (Imitrex): not a benefit
  • Zolmitriptan (Zomig Rapimelt): not a benefit

1 more in the class list below

Auro-Eletriptan · DIN 02479478 · 40mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Eletriptan · DIN 02479478 Manufacturer: Auro Pharma Inc.; listing date 2019-04-30 Health Canada: Marketed since 2019-02-01 · brand AURO-ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97014 · Verify on the e-Formulary ↗ (DIN 02479478)

Source record
DIN 02479478: Auro-Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200050; group id 537; item number 1455; lccId None; manufacturer id AUR Source form: Tab; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479478 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97014
Interchangeable products
Apo-Eletriptan · DIN 02386062 · not recorded Apo-Eletriptan Tablets · DIN 02518023 · not recorded Eletriptan · DIN 02511274 · not recorded Gd-Eletriptan · DIN 02342243 · not recorded Jamp Eletriptan · DIN 02493691 · not recorded Relpax · DIN 02256304 · not recorded Teva-Eletriptan · DIN 02382105 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:92 Miscellaneous Central Nervous System Drugs) and how they are covered

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PIZOTYLINE Some products covered without a code (check the product listing): ATOMOXETINE HCL, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 28:92 Miscellaneous Central Nervous System Drugs

ALMOTRIPTAN

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6.25mg, 12.5mg · Tab

FROVATRIPTAN SUCCINATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Tab

NARATRIPTAN HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2.5mg · Tab

RIZATRIPTAN

· 44 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

SUMATRIPTAN SUCCINATE

· 37 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6mg/0.5mL, 25mg, 50mg, 100mg · Inj Sol-Pref Syr 0.5mL Pk, Tab

ZOLMITRIPTAN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Orally Disintegrating Tab, Tab

PIZOTYLINE

· 1 products · General benefit · strengths: 1mg · Tab

ATOMOXETINE HCL

· 59 products · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) · strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg · Cap

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

· 28 products · General benefit (19), Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2) · strengths: 0.25mg, 0.5mg, 1mg, 1.5mg · Tab

ACAMPROSATE CALCIUM

· 1 products · Limited Use, codes 531 · strengths: 333mg · DR Tab

ENTACAPONE

· 4 products · Limited Use, codes 367 · strengths: 200mg · Tab

DIMETHYL FUMARATE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 120mg, 240mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:92 and 1 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults RELPAX (eletriptan hydrobromide) is indicated for the acute treatment of migraine with or without aura in adults. RELPAX tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of RELPAX tablets have not been established for cluster headache, which is present in an older, predominantly male population. Pediatrics (< 18 years of age) The safety and efficacy of RELPAX in children has not been established and its use in this age group is not recommended. (See WARNINGS and PRECAUTIONS) Geriatrics (> 65 x years of age) Experience of the use of RELPAX in patients aged over 65 years is limited. Therefore the use of RELPAX in patients over 65 years is not recommended. (See WARNINGS and PRECAUTIONS). https://pdf.hres.ca/dpd_pm/00072295.PDF PM date: not printed or not captured Source product: RELPAX; DIN 02256290; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Auro-Eletriptan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026